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Transgenerational epigenetic inheritance results from incomplete erasure of parental epigenetic marks during
epigenetic reprogramming at fertilization. The significance of this phenomenon, and the mechanism by which it
occurs, remains obscure. Here, we show that genetic mutations in Drosophila may cause epigenetic alterations that,
when inherited, influence tumor susceptibility of the offspring. We found that many of the mutations that affected
tumorigenesis induced by a hyperactive JAK kinase, Hop
Tum-l, also modified the tumor phenotype epigenetically,
such that the modification persisted even in the offspring that did not inherit the modifier mutation. We analyzed
mutations of the transcription repressor Kru ¨ppel (Kr), which is one of the hop
Tum-l enhancers known to affect ftz
transcription. We demonstrate that the Kr mutation causes increased DNA methylation in the ftz promoter region,
and that the aberrant ftz transcription and promoter methylation are both transgenerationally heritable if Hop
Tum-l
is present in the oocyte. These results suggest that genetic mutations may alter epigenetic markings in the form of
DNA methylation, which are normally erased early in the next generation, and that JAK overactivation disrupts
epigenetic reprogramming and allows inheritance of epimutations that influence tumorigenesis in future
generations.
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Introduction
Epigenetic regulation of gene expression refers to repres-
sion or activation of gene expression via covalent modiﬁca-
tions of DNA or histones, such as methylation or acetylation,
without changing the DNA sequence of the gene [1–3].
Epigenetic modiﬁcations are usually stably heritable through
subsequent cell divisions, resulting in permanent changes in
gene expression proﬁles, such as those associated with
terminal differentiation. However, at critical stages in normal
development or disease situations, cells undergo genome-
wide epigenetic reprogramming, erasing preexisting epige-
netic marks and establishing a new set of marks. For instance,
major epigenetic reprogramming occurs at fertilization prior
to zygotic development, at dedifferentiation that leads to
cancer development, and during somatic cell nuclear trans-
fer, a procedure used for cloning or obtaining embryonic
stem cells [4–7].
However, epigenetic marks are not always completely
erased from one generation to the next. For instance,
genomic imprinting, where clusters of genes or whole
chromosomes are preferentially inactivated depending on
their parental origin [8,9], can be considered an exception to
epigenetic reprogramming, because in this case parental
epigenetic markings are retained in the zygote. Loss of
imprinting has been shown to increase the likelihood that
cancer will develop [10–12]. Furthermore, human diseases,
such as Prader-Willi and Angelman syndromes [13] and
hereditary nonpolyposis colorectal cancer [14], are associated
with germline inheritance of epimutations. Though trans-
generational epigenetic inheritance has been documented for
a variety of eukaryotic organisms ranging from plants to
humans [15], the precise mechanisms that regulate epigenetic
marking and erasure, as well as those that protect certain
epigenetic marks from being reset, are not clear.
We have previously undertaken a genetic approach in
order to identify genes that are important for hop
Tum-l-
induced tumorigenesis in Drosophila, and in the process, have
found that JAK signaling globally counteracts heterochroma-
tin formation [16]. Further analyses of the identiﬁed
mutations indicated that a number of those mutations that
genetically modify hop
Tum-l tumorigenicity also do so epige-
netically. In fact, hop
Tum-l itself plays an essential role in the
maintenance of parental origin epigenetic alterations that
subsequently affect tumorigenesis in a transgenerational
manner. These results indicate a novel function for the
hop
Tum-l oncogene: it interferes with the epigenetic reprog-
ramming process.
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Paternal-Effect Modification of Tum-l Tumorigenicity
We previously conducted a genetic screen for modiﬁers of
the hop
Tum-l hematopoietic tumorigenic phenotype and
identiﬁed 37 modiﬁer mutations [M(Tum-l)] that dominantly
enhanced or suppressed hop
Tum-l tumorigenesis in hop
Tum-l/þ;
M(Tum-l)/þ transheterozygotes [16]. Hematopoietic tumors in
hop
Tum-l-containing ﬂies were quantiﬁed by tumor index (TI)
(see Materials and Methods and also [16]). Interestingly, many
of the M(Tum-l) mutations (24/37) exhibited paternal-effect
modiﬁcation of hop
Tum-l tumorigenicity, such that when
hop
Tum-l/þ females were mated to males heterozygous for the
modiﬁer mutation (M[Tum-l]/þ), tumorigenesis associated with
hop
Tum-l was modiﬁed (enhanced or suppressed) in the F1
generation regardless of the inheritance of M(Tum-l) (Table
1). The transgenerational effects were conﬁrmed with
rebalanced stocks, indicating that they are unlikely to be
due to different genetic backgrounds. Since little or no
paternal cytoplasmic proteins are carried in the sperm, the
observed paternal effects on the zygote suggest an epigenetic
mechanism. Possibly, the M(Tum-l) mutations caused epige-
netic alterations in the paternal chromosomes and these
epigenetic changes were maintained through male meiosis
and transmitted to the F1 generation, thereby inﬂuencing
hop
Tum-l tumorigenicity.
Transgenerational Tumor Modification Depends on
Maternal hop
Tum-l Mutation
To understand the nature of the transgenerational epi-
genetic modiﬁcation of hop
Tum-l tumorigenicity by the M(Tum-
l) mutations, we conducted a detailed analysis of Kr, which is
one of the ﬁrst zygotically transcribed ‘‘gap’’ genes whose
activity is required for the correct segmentation of the
embryo [17]. First, we tested two loss-of-function alleles of Kr
(Kr
1 and Kr
2) and found that they both enhanced hop
Tum-l
genetically and epigenetically (Figure 1A; unpublished data),
conﬁrming Kr as an E(Tum-l) with epigenetic effects.
To rule out any genetic background effects, we extensively
outcrossed a Kr
1 allele, and isogenized and rebalanced it over
a CyO balancer chromosome that in previous testing showed
no enhancement of hop
Tum-l (see Materials and Methods). The
new iso-Kr
1/CyO stock again enhanced hop
Tum-l tumorigenicity
both genetically and epigenetically, such that when hop
Tum-l/þ
females were crossed to iso-Kr
1/CyO males both hop
Tum-l/þ;
Kr
1/þ and hop
Tum-l/þ; þ/CyO progeny exhibited signiﬁcantly
higher TI (Figure 1B, columns 2 and 3). Interestingly, when F1
males of þ/Y; þ/CyO, which did not inherit Kr
1,w e r e
backcrossed to hop
Tum-l/þfemales, we found that the enhance-
ment persisted in the F2 generation in the absence of Kr
1, but
diminished in the F3 (Figure 1B, columns 4 and 5). Since half
and a quarter of the P0 paternal DNA contents (originally
exposed Kr
1) are inherited in the F2 and F3 generation,
respectively, the diluting effect of the enhancement in the
absence of the original mutation (Kr
1) is consistent with the
idea that the modiﬁcation is epigenetic in nature and is
distributed genome wide at multiple loci. To rule out the
possibility that Kr
1 induced genome-wide genetic mutations,
we conducted the reciprocal cross, mating iso-Kr
1/CyO
females with rare escaper hop
Tum-l/Y males. We found that
Kr
1 enhanced hop
Tum-l only genetically but not epigenetically,
such that the TI increased in hop
Tum-l/þ; Kr
1/þ but not in
hop
Tum-l/þ; þ/CyO female progeny ﬂies (Figure 1C). The result
of the reciprocal cross conﬁrms that the modiﬁcation is
epigenetic in nature, as genetic mutations (changes in DNA
sequence) would not be reversible under normal circum-
stances. However, such a result could also suggest a parent-
speciﬁc effect of Kr on the hop
Tum-l mutation.
To test whether the epigenetic effects of Kr
1 are speciﬁc for
the male genome, we mated hop
Tum-l/þ; Kr
1/CyO recombinant
females to wild-type males. In this cross, the tumor phenotype
associated with hop
Tum-l was enhanced in both hop
Tum-l/þ; Kr
1/þ
and hop
Tum-l/þ; CyO/þ progeny ﬂies (Figure 1D), indicating
that the presence of Kr
1 in the female parent can also have
epigenetic effects on hop
Tum-l tumorigenicity in the F1
generation. Thus, it appeared that Kr
1 was capable of
epigenetically altering both male and female genomes, and
these alterations could be transmitted through both male and
female meioses to the F1. However, the inheritance and/or
ability of these parental origin alterations to modify hop
Tum-l
tumorigenicity epigenetically in the F1 progeny appeared to
depend on the presence of hop
Tum-l as a maternal mutation.
Transgenerational Epigenetic Effects of Histone
Deacetylase Inhibitors on Tum-l Tumorigenicity
To further test the ability of maternal hop
Tum-l to maintain
parental origin epigenetic changes, we examined the effects
of histone deacetylase (HDAC) inhibitors on hop
Tum-l tumor-
igenicity. Since Rpd3, encoding an HDAC, was identiﬁed as
one of the genes which, when mutated, exhibited both genetic
and epigenetic enhancement of hop
Tum-l tumorigenicity (Table
1), we reasoned that the epigenetic effect of an Rpd3
mutation on hop
Tum-l tumorigenicity might be mimicked by
HDAC inhibitors such as tricostatin A (TSA) and sodium
butyrate. Indeed, TSA treatment caused increased levels of
acetylated histone H3 (Figure 1E), and increased the tumor
index of hop
Tum-l/þ ﬂies from 0.38 to 0.96 6 0.06 (p , 0.01).
Consistent with a transgenerational epigenetic effect, when
wild-type ﬂies that had been treated with TSA were mated
with untreated hop
Tum-l/þfemales and the progeny were raised
in the absence of the drug, the TI of hop
Tum-l/þF1 progeny was
also signiﬁcantly increased (Figure 1F). As with Kr
1,n o
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Author Summary
It is well known that many genetic mutations in oncogenes or tumor
suppressors can cause or greatly increase a person’s susceptibility to
cancer. It is generally assumed that persons should feel relieved if
they have not inherited the particular ‘‘cancer-causing’’ mutation
carried by their parents. However, we found that, under certain
circumstances, fruit flies carrying tumor suppressor gene mutations
can pass the increased tumor risk to all offspring, even those that
have not inherited the particular mutation. A likely scenario is that
many genetic mutations can lead to epigenetic alterations, that is,
changes in the chemical modifications of DNA or the proteins that
bind to DNA in the chromosomes, and these changes can have
global effects on cell function. Normally, these epigenetic alterations
are wiped out and reset in the early embryo, but under certain
circumstances such alterations can be inherited. Interestingly, we
found evidence that a particular oncoprotein, an overactivated form
of a cell-signaling molecule called JAK kinase, can counteract the
epigenetic resetting program that normally operates in the early
embryo. Thus, the failure of epigenetic reprogramming allows the
inheritance of parental epigenetic alterations that affect suscepti-
bility to tumors.epigenetic effect was found in the reciprocal cross (Figure
1F), suggesting that the presence of hop
Tum-l in the early
embryo is important for TSA treatment to have a trans-
generational epigenetic effect on hop
Tum-l tumorigenicity. A
similar transgenerational epigenetic effect on hop
Tum-l tumor-
igenicity was also found with another HDAC inhibitor,
sodium butyrate (unpublished data).
Maternal hop
Tum-l Mutation Maintains Kru ¨ppel Mutant
Phenotypes in Its Absence
To investigate the maternal hop
Tum-l-dependent transge-
nerational inheritance of epigenetic changes at the level of
gene expression, we examined the effects of hop
Tum-l on Kr-
dependent expression of the pair-rule gene fushi-tarazu (ftz),
which encodes a homeodomain protein required for embry-
onic patterning [18]. It has been shown that Kr heterozygous
embryos exhibit defects in ftz expression [19]. In wild-type
embryos, ftz is expressed in seven stripes at the onset of
gastrulation (Figure 2A). In Kr
1/þembryos, however, ftz stripe
3 is narrow or weak (Figure 2B; also see [19]). The same ftz
stripe 3 phenotype was found in Kr
2/þ embryos (unpublished
data). We wondered whether the defects in ftz expression
might involve epigenetic alterations, and whether these
defects could be passed to the next generation in the
presence of maternal hop
Tum-l mutation. Indeed, we found
that the ftz promoter region is differentially methylated in Kr
heterozygotes (see below).
We reasoned that if hop
Tum-l promotes transmission of
parental origin epigenetic alterations to the next generation,
then the ftz stripe 3 defect caused by Kr
1 could be retained in
embryos from hop
Tum-l/þ mothers and Kr
1/þ fathers that did
not inherit Kr
1. To test this, we examined ftz expression from
a ftz-lacZ transgene carried on the CyO balancer chromosome,
which contains the Kr
þ allele and segregates from Kr
1 in the
F1 when Kr
1/CyO ftz-lacZ ﬂies are used as a parent. In embryos
from male and female Kr
1/CyO ftz-lacZ ﬂies, 70% (n¼61/87) of
Table 1. Genetic and Epigenetic Modification of hopTum-l Tumorigenicity
Category Modifier of Tum-l Allele Tested Tumor Index Epigenetic Effect
Tum-l/þ; m/þ Tum-l/þ; Bal./þ
E(tum-l) Tp(3;Y)ry506-85C — 1.89 6 0.16 0.95 6 0.20 þ
unchained unch[k15501] 1.74 6 0.19 1.20 6 0.11 þ
TBP-associated factor 1 Taf1[1] 1.63 6 0.06 0.74 6 0.06 þ/ 
Df(2R)H3C1 — 1.58 6 0.09 0.60 6 0.09  
Cdc27 Cdc27[L7123] 1.45 6 0.05 1.02 6 0.08 þ
abnormal wing discs awd[j2A4] 1.42 6 0.06 0.41 6 0.10  
Ets at 97D Ets97D[tne-4] 1.39 6 0.12 0.90 6 0.08 þ
spindle E spn-E[1] 1.38 6 0.08 0.71 6 0.12  
HEM-protein Hem[03335] 1.34 6 0.09 0.92 6 0.11 þ
Toll Tl[r4] 1.33 6 0.04 1.00 6 0.19 þ
sallimus sls[1] 1.31 6 0.08 0.47 6 0.09  
Kru ¨ppel Kr[1] 1.29 6 0.16 1.24 6 0.14 þ
plume plume[k00308] 1.28 6 0.11 0.35 6 0.05  
rhino rhi[02086] 1.24 6 0.12 1.01 6 0.14 þ
Suppressor of variegation 2–5 Su(var)205[5] 1.18 6 0.06 0.65 6 0.26 þ/ 
Rpd3 Rpd3[04556] 1.17 6 0.08 0.68 6 0.21 þ/ 
bellwether blw[1] 1.07 6 0.06 0.92 6 0.05 þ
knirps kni[6] 0.98 6 0.07 0.84 6 0.06 þ
Suppressor of variegation 3–4 Su(var)3–4[1] 0.94 6 0.04 0.81 6 0.08 þ
moira mor[1] 0.93 6 0.06 1.08 6 0.19 þ
hairy h[08247] 0.91 6 0.07 1.04 6 0.22 þ
labial lab[4] 0.91 6 0.06 0.86 6 0.03 þ
polo polo[01673] 0.89 6 0.05 0.49 6 0.12  
Deformed Dfd[6] 0.88 6 0.05 0.50 6 0.13  
Enhancer of bithorax E(bx)[ry122] 0.87 6 0.21 0.77 6 0.26 þ
Vacuolar Hþ-ATPase 55kD B subunit Vha55[j2E9] 0.85 6 0.13 0.60 6 0.19 þ/ 
gooseberry gsb[01155] 0.84 6 0.06 0.96 6 0.17 þ
Protein tyrosine phosphatase 69D Ptp69D[1] 0.84 6 0.04 0.39 6 0.04  
Suppressor of variegation 3–9 Su(var)3–9[1] 0.83 6 0.03 0.82 6 0.27 þ
domino dom[k08108] 0.82 6 0.03 0.89 6 0.01 þ
piwi piwi[06843] 0.82 6 0.04 0.36 6 0.05  
Suppressor of variegation 2–10 Su(var)2–10[03697] 0.80 6 0.04 0.34 6 0.13  
Su(Tum-l) even-skipped eve[3] 0.08 6 0.02 0.05 6 0.02 þ
baboon babo[32] 0.02 6 0.01 0.25 6 0.14 –
Serrate Ser[VX82] 0.01 6 0.00 0.01 6 0.00 þ
Df(3L)Exel6111 – 0.00 6 0.00 0.02 6 0.01 þ
lethal with a checkpoint kinase lack[KG07014] 0.00 6 0.00 0.34 6 0.02 –
Tum-l/FM7 females were mated to mutant/Balancer (m/Bal.) males. Mutant alleles used for testing are listed in column 2. Tumor indices were calculated for Tum-l/þ; m/þF1 progeny flies
and their Tum-l/þ; Bal./þ siblings. Epigenetic effect (column 5) was assessed by the tumor phenotypes of the Tum-l/þ; Bal./þ F1 progeny flies. Epigenetic effects are indicated by the
following categories. (þ): TIs of the Tum-l/þ; Bal./þF1 flies that were significantly different from control cross (Tum-l/FM7 females crossed to wild-type males) but not from their Tum-l/þ;m / þ
siblings. (þ/ ): the TIs were significantly different from both the control cross and siblings. ( ): the TIs were significantly different from the siblings but not from the control cross. Chi-
squared test was used for analyzing statistical significance.
doi:10.1371/journal.pgen.0030151.t001
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Epigenetic Inheritance of Tumor RiskFigure 1. Epigenetic Enhancement of hop
Tum-l Tumorigenicity by Kr
1 or TSA Treatment Requires Maternal hop
Tum-l
(A) Representative F1 progeny adult flies of indicated genotypes with blood tumors (black masses; arrows) in the abdomen are shown. The parents of
these flies were hop
Tum-l/þ females and wild type males (left), or hop
Tum-l/þ females and Kr
1/CyO males (center and right).
(B–D) The tumor indices of progeny flies (genotypes are indicated in bottom right) are shown as mean and standard deviation of at least three
independent crosses. ‘‘Control cross F1’’ were from hop
Tum-l/þ crossed to wild type. Parental genotypes are indicated on the top. FM7 and CyO are
marked balancer chromosomes for the X and second chromosomes carrying a wild-type copy of the hop and Kr genes, respectively. Note that when
hop
Tum-l was inherited from the mother (B, D), but not from the father (C), Kr
1 epigenetically enhanced hop
Tum-l tumorigenicity.
(E) Total protein extracts from adult flies raised on food containing 4.5 lM TSA were subjected to SDS-PAGE and blotted with anti-acetyl-H3. The membrane
was stripped and reblotted with anti-H3 (full-length gel image is shown in Figure S1). Quantification of three independent blots is shown to the right.
(F) Tumor indices of F1 progeny from wild-type flies treated or untreated (control) with TSA and hop
Tum-l/þ females or males as shown. The F1 were
raised in the absence of TSA. Tumors were counted in F1 that inherited hop
Tum-l. Note the parent-of-origin differential effects on the tumorigenesis of F1
flies. Three independent crosses with .200 progeny from each cross were counted. *, p , 0.01; **, p , 0.001, Student’s t-test.
doi:10.1371/journal.pgen.0030151.g001
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þ embryos exhibited the typical Kr
1 heterozygous
defects, characterized by weakened or narrowed stripe 3
expression (Figure 2B), suggesting that all embryos that are
genotypically Kr
1/CyO ftz-lacZ exhibit the stripe 3 defect.
When Kr
1/CyO ftz-lacZ ﬂies were crossed to wild-type ﬂies, in
the F1 embryos, ftz-lacZ was expressed in seven stripes
identical to those in the wild-type background, such that
these stripes were more or less evenly spaced and similar in
intensity (Figure 2A; n ¼ 54). When hop
Tum-l females were
mated to þ/CyO ftz-lacZ males, we found wild-type ftz-lacZ
pattern and no stripe 3 defects similar to those in Kr
1
heterozygotes in the F1 embryos (Figure 2C; n¼78). Notably,
although the JAK/STAT pathway is involved in regulating
even-skipped stripe 3 expression [20,21], ftz expression seemed
not affected in hop
Tum-l mutants. This is consistent with a lack
of STAT-binding sites in the ftz promoter region (unpub-
lished data). However, when Kr
1/CyO ftz-lacZ males were mated
to hop
Tum-l females, 94% of the F1 b-gal
þembryos retained the
stripe 3 defect characteristic of Kr
1 heterozygotes (Figure 2D;
n ¼ 48/51). Since in this mating scheme ftz-lacZ segregated
from Kr
1, embryos that expressed the ftz-lacZ trangene would
not inherit Kr
1 and were genotypically þ/þ for the Kr locus.
Thus, the presence of hop
Tum-l caused retention of the Kr
1-
speciﬁc defective ftz expression pattern in embryos that did
not inherit the Kr
1 mutation. These results demonstrate that
hop
Tum-l can cause transgenerational inheritance of epigenetic
changes at a transcriptional level.
Transgenerational Inheritance of Kr-Induced ftz Promoter
Methylation
To identify the epigenetic alterations caused by Kr
mutations, we examined the DNA methylation status of the
620-bp minimal ftz enhancer in the ftz-lacZ transgene, as the
expression of this ftz-lacZ is epigenetically modiﬁed by Kr
1.
DNA methylation is the predominant epigenetic modiﬁca-
tion, and methylation of CpG islands is responsible for gene
silencing and genomic imprinting in mammals [5–7]. There is
evidence for the presence of DNA methylation in Drosophila
[22,23]. Drosophila has a Dnmt2-like DNA methyltransferase
that mediates methylation of cytosine residues in vivo [24],
although the biochemical activity of Drosophila Dnmt2 as a
DNA methyltransferase is still to be shown. Methylated
cytosines in both CG and CT dinucleotides have been found
in many transposons and repetitive sequences in Drosophila
genomic DNA [25], and increased promoter DNA methyl-
ation is associated with gene silencing [26].
We ﬁrst assessed the methylation status of the ftz minimal
enhancer (Figure 3A) by digesting total genomic DNA with a
methylation-sensitive restriction enzyme BstUI, which cuts
unmethylated but not methylated CGCG sequences, followed
by quantiﬁcation of the undigested DNA by PCR. By
comparing the time courses of BstUI digestion of genomic
DNA samples isolated from Kr
þ/  versus wild-type control
ﬂies, we concluded that the former is more resistant to BstUI
digestion (Figure 3B and 3C, top panels). Digestion of the
same DNA samples with a methylation-insensitive restriction
enzyme HaeIII produced no differences between the two
samples (Figure 3B and 3C, bottom panels). These results
suggest that the minimal enhancer of ftz-lacZ in Kr
þ/  ﬂies is
more methylated than in wild-type ﬂies.
We next investigated whether the Kr-dependent differ-
ential methylation of the ftz minimal enhancer can be passed
to the next generation. We crossed Kr
1/CyO ftz-lacZ ﬂies to
hop
Tum-l/þ and wild type females, respectively, and isolated
genomic DNA from the F1 ﬂies that inherited the ftz-lacZ
transgene. We analyzed the methylation status of the 620-bp
minimal ftz enhancer using methylation-sensitive and
-insensitive restriction digests as described above. Indeed,
we found the ftz enhancer in F1 ﬂies of hop
Tum-l/þfemales and
Kr
1/CyO ftz-lacZ males was more resistant to a methylation-
sensitive restriction enzyme than the ftz enhancer in F1 ﬂies
of þ/þ females and Kr
1/CyO ftz-lacZ males (Figure 3D and 3E),
consistent with the idea that hop
Tum-l promotes transgenera-
tional inheritance of epigenetic changes.
We employed a second method to conﬁrm that the
promoter of the ftz-lacZ transgene has increased DNA
methylation in Kr mutants and that this methylation status
is transgenerationally inheritable in the presence of hop
Tum-l
maternal mutation. We isolated total genomic DNA from
embryos of different parental genotypes, digested with
restriction enzymes, and incubated with antibodies against
methylated cytosine. Quantiﬁcation of immunoprecipitated
DNA indicates that that the ftz-lacZ fragment was more
methylated in embryos of Kr
1/CyO ftz-lacZ ﬂies (Figure 3F) and
the higher levels of methylation was maintained in embryos
from Kr
1/CyO ftz-lacZ fathers and hop
Tum-l mothers (Figure 3G).
Finally, to further demonstrate the differential methylation
of the ftz minimal enhancer in different genetic backgrounds
or pedigrees, we treated the genomic DNA samples with
Figure 2. Maternal hop
Tum-l Maintains Kr
1 Mutant Phenotypes in Absence
of Kr
1
ftz expression pattern in stage 4 embryos from a ftz-lacZ transgene
carried on the CyO balancer chromosome was analyzed by anti-b-gal
staining. Embryos were produced by crosses indicated to the left. Note
the wild-type ftz expression pattern in (A) and (C). Also note that the ftz
stripe 3 (arrow) is faint or missing Kr
1 heterozygotes (B) or in progeny
from hop
Tum-l/þ females and Kr
1/ftz-lacZ males (D), which did not inherit
Kr
1.
doi:10.1371/journal.pgen.0030151.g002
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(T), and then cloned and sequenced independent clones for
each sample. Sequencing results indicated the presence of
two CG (or CT)-rich ‘‘islands’’ in the ftz minimal enhancer
that are preferentially methylated in Kr
þ/  samples or in
embryos of Kr
1/CyO ftz-lacZ father and hop
Tum-l mothers
(Figure 4). Thus, Kr mutations indeed induce epigenetic
alterations, as exempliﬁed by increased DNA methylation in
the ftz minimal enhancer, and such alterations are normally
erased, but are transmitted to the next generation if an
overactivated JAK kinase is present in the early embryo.
5-Aza-dC Treatment Promotes Tumorigenesis but Inhibits
the Epigenetic Effects of Kr on hop
Tum-l Tumorigenicity
Since the epigenetic effects of Kr mutations involve DNA
methylation, we investigated the effects of inhibiting DNA
methylation on the ability of Kr mutations in promoting
hop
Tum-l tumorigenesis. We raised ﬂies in food containing the
Figure 3. Increased Methylation of ftz Regulatory Region in Kr
þ/  Animals and Its Inheritance
(A) Schematic representation of the ftz-lacZ reporter, showing the minimal ftz 59 regulatory region previously shown to be sufficient to drive expression
of a ftz-lacZ reporter transgene in ftz patterns [30]. Arrows above and below the horizontal line represent PCR primers used to amplify a 778-bp
fragment, encompassing the 620-bp minimal ftz enhancer (see Figure S2 for sequence). Bent arrow indicates the start of the lacZ sequence. Vertical bars
above and below the line represent positions of recognition sequences for restriction enzymes BstUI (CGCG) and HaeIII (GGCC), respectively.
(B–E) Time courses of restriction digests of genomic DNA with enzymes sensitive (BstUI) or insensitive (HaeIII) to methylated DNA are shown as agarose
gel pictures and quantifications. Genomic DNA was isolated from Kr
1/CyO ftz-lacZ andþ/CyO ftz-lacZ (wild-type control) adult flies (B, C), or from the F1
progeny flies of Kr
1/CyO ftz-lacZ males crossed to hop
Tum-l/þ females or wild-type females (D, E), and digested with the indicated enzymes for the
indicated times (minutes). Digested DNA was amplified with PCR primers shown in (A) and run on an agarose gel. Note that the genomic DNA from
Kr
þ/  flies or from the F1 progeny of hop
Tum-l/þ females and Kr
1/CyO ftz-lacZ males is more resistant to BstUI digestion than the controls.
(F, G) Digested genomic DNA purified from embryos was immunoprecipitated by antibodies to methylated cytosine and amplified by PCR primers
shown in (A). Embryos derived from wild-type or Kr
þ/  parents (F), or from Kr
1/ftz-lacZ males crossed to wild-type (top) or Tum-l/þ(bottom) females (G)
were used for DNA isolation. Note the presence of higher levels of 5-meC in the ftz-lacZ promoter in Kr
þ/  embryos or in those from Tum-l/þ females
crossed to Kr
1/ftz-lacZ males.
doi:10.1371/journal.pgen.0030151.g003
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aza-dC) and determined the effects of drug treatment on
hop
Tum-l–dependent blood tumor formation. When raised at
100 lM 5-aza-dC (a nonlethal dose), hop
Tum-l/þ ﬂies exhibited
dramatically increased tumors compared with untreated
hop
Tum-l/þ ﬂies, with TI increased from 0.41 6 0.05 (untreated;
n ¼ 116) to 1.27 6 0.15 (treated; n ¼ 68; p , 0.001). Such
results are in line with TSA treatment (see above). Similar to
the effects of TSA treatment, when wild-type male ﬂies raised
in 5-aza-dC were crossed to hop
Tum-l/þ females and allowed to
produce eggs in the absence of the drug, the F1 ﬂies exhibited
increased TIs (Figure 5), but no TI increase was detected in
the reciprocal cross (unpublished data), suggesting a maternal
hop
Tum-l-dependent transgenerational inheritance. Interest-
ingly, we found that treatment with 5-aza-dC, although by
itself promotes hop
Tum-l tumorigenesis, abolished the ability of
Kr mutations to epigenetically enhance tumors, such that
when Kr
1/CyO male ﬂies raised on 5-aza-dC food were crossed
to hop
Tum-l/þ females, the epigenetic effects (associated with
CyO), but not the genetic effects of Kr, were abolished (Figure
5). Thus, the DNA methylation methyltransferase inhibitor 5-
aza-dC both promotes hop
Tum-l tumorigenesis and inhibits Kr
epigenetic effects. These results suggest that hop
Tum-l-induced
blood tumors can be both enhanced by a general loss of
genomic DNA methylation and suppressed by preventing Kr
mutation–induced methylation in speciﬁc promoters.
Discussion
We have investigated the effects of genetic and epigenetic
mutations on the tumorigenicity of the Drosophila hemato-
poietic oncogene hop
Tum-l, and found that hop
Tum-l and its
modiﬁer mutations mutually inﬂuence each other, both
Figure 4. Methylation of CG/T ‘‘Islands’’ in the ftz Minimal Enhancer
Genomic DNA isolated from animals of different genotypes was treated with sodium bisulfite and independent clones of the ftz-lacZ were sequenced.
Sequencing results of two CG- or CT-rich boxes in the ftz minimal enhancer from animals of indicated genotypes are shown in red boxes, with the
original sequences on top. Numbers above the sequences indicate positions from the forward PCR primer (see Figure S2 for primer sequence). Numbers
to the left indicate sample numbers of independent clones. Unmethylated C’s, which are converted to T’s following bisulfite treatment, are indicatedb y
open circles. Methylated C’s, which remain as C’s following bisulfite treatment, are represented as filled circles. (A) Genomic DNA was isolated from Kr
1/
CyO ftz-lacZ andþ/CyO ftz-lacZ (wild-type control) adult flies (clones 1–15) and embryos (clones 16–20), and (B) from embryos of Kr
1/CyO ftz-lacZ males
crossed to hop
Tum-l/þfemales or wild-type females. Note that there are more unconverted C’s in lower panels, indicating higher levels of methylation in
these samples. Low background levels (,1%) of unconverted C’s were found in other regions for both samples. (C) Sample chromatograms with clone
number indicated.
doi:10.1371/journal.pgen.0030151.g004
Figure 5. Effects of the Methyltransferase Inhibitor 5-Aza-dC on
Tumorigenesis
Wild-type or Kr
1/CyO flies were raised in food supplemented with (þ)o r
without ( ) 5-aza-dC. Male flies of indicated genotypes were then
crossed to hop
Tum-l/þfemales and the F1 was raised in regular food in the
absence of 5-aza-dC. F1 flies of the indicated genotypes were scored for
the presence of melanotic tumors. TIs are shown as average 6 standard
deviation. * indicates significant difference by Chi-squared test.
doi:10.1371/journal.pgen.0030151.g005
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that a Kr mutation that enhances hop
Tum-l tumorigenicity
induces ftz promoter methylation, which is associated with
repression of ftz stripe 3, and that Tum-l promotes trans-
generational inheritance of ftz stripe 3 silencing in the F1
generation in the absence of the Kr mutation.
Taken together, these results suggest that the oncogenic
JAK kinase encoded by hop
Tum-l is able to antagonize a cellular
program that erases epigenetic markings of parental origin,
allowing such epigenetic alterations to be maintained in the
F1 even in the absence of the original genetic mutation. The
epigenetic alterations in turn inﬂuence the risk of hop
Tum-l-
induced tumorigenesis in the F1 generation.
Epigenetic Effects of hop
Tum-l Modifier Mutations
Many of the M(Tum-l) genes that exhibited paternal-effect
modiﬁcations encode products with known chromatin
remodeling functions. These include HP1, Rpd3, and several
Suppressor of variegation (Su[var]) mutations. It is conceiv-
able that ﬂies heterozygous for these mutations have altered
chromatin states that could directly inﬂuence the epigenetic
state of the zygote, leading to paternal effects as shown
recently in mice [27]. However, the M(Tum-l) genes that
exhibited epigenetic effects on Tum-l tumorigenicity also
include those whose functions in chromatin modiﬁcation are
not obvious. These include transcription factors such as Kr
and signaling molecules such as the Notch ligand Serrate
(Ser). This observation suggests that genetic mutations in
genes other than those encoding chromatin remodeling
proteins may also cause epigenetic alterations.
Although Kr is expressed only in 20% of the early embryo,
lacking Kr causes profound patterning defects, resulting in
deletion or defects in over 70% of embryonic segments [28].
As a ﬁrst zygotically expressed ‘‘gap’’ gene, Kr is in the top tier
of the regulatory hierarchy that controls pattern formation of
the whole organism [28]. Thus, Kr mutations can affect
expression of genes that are not directly regulated by Kr. A
Kr neomorphic allele (Kr
if) has been shown to affect eye
development by an epigenetic mechanism [29]. Our results
indicate that the Kr mutation, which likely acts early on,
results in the establishment of an epigenetic signature in the
genome in the form of methylation of particular promoters,
such as the ftz promoter. Repression of certain ‘‘tumor
suppressor genes’’ may explain the enhancement of the
hop
Tum-l tumorigenic phenotype by Kr mutations. As an
epigenetic modiﬁcation, DNA methylation is believed to be
mitotically stable. In support of this notion, we detected
similar methylation patterns in the ftz-lacZ promoter in
embryos and adult ﬂies of Kr heterozygotes (Figure 4).
Although we have not directly examined germ cells, the
transgenerational phenomenon suggests that the Kr-depend-
ent epigenetic signature extends to germ cells, which give rise
to sperm and eggs. We envision the possibility that the
epigenetic signature of germ cells is established early together
with somatic cells, and can be affected by mutations in Kr,
which might have a global reach in the early embryo.
Alternatively, there is constant communication between germ
cells and somatic cells during animal development, such that
their epigenetic states will stay in ‘‘sync.’’ The precise
mechanisms by which germ cells acquire the epigenetic states
of somatic cells remain to be investigated.
Requirement of Maternal hop
Tum-l for Inheritance of
Epigenetic Mutations
When hop
Tum-l is inherited from the mother, its product, a
hyperactive JAK kinase, is present in the embryo from the
very beginning as a maternal contribution. In contrast, when
inherited from the father, the hop
Tum-l gene product is not
present in the early embryo but is expressed as a zygotic gene.
Zygotic genes are not transcribed until the midblastula
transition or later. The parent-of-origin effect of hop
Tum-l on
the ability of Kr
1 to modify its tumorigenicity suggests the
following scenario. The M(Tum-l) mutations are capable of
altering the state of the chromatin, resulting in epigenetic
changes in the genome. These ‘‘epigenetic marks’’ can be
maintained through mitosis and meiosis and transmitted to
the F1 progeny, where they are normally erased in the zygote
during early embryogenesis. However, the hop
Tum-l mutation,
if present in the early embryo as a maternal-effect mutation,
is able to preserve certain epigenetic alterations of parental
origin. In other words, hop
Tum-l may play a role in counter-
acting a mechanism that erases epigenetic marks of parental
origin during early embryogenesis.
Materials and Methods
Fly stocks and genetics. All crosses were carried out at 25 8Co n
standard cornmeal/agar medium. All ﬂy stocks, including hop
Tum-l,K r
alleles, CyO [ftz-lacZ], and the Bloomington Deﬁciency Kit Stocks, are
from the Bloomington Drosophila Stock Center (http://ﬂystocks.bio.
indiana.edu/). Accession numbers for mutations used in this study are
list in Table S1.
Hematopoietic tumors induced by hop
Tum-l were scored in adult
ﬂies, which manifest as melanotic masses most frequently found in
the abdomen (see Figure 1A), but were also found in other parts of
the body. Tumors of all sizes and locations were scored. Typically
more than 200 progeny ﬂies were scored for each cross. More than
two independent crosses were scored and the results averaged.
Tumorigenicity was quantiﬁed by TI, which is deﬁned as the sum of
tumor size times occurrence, and divided by the total number of ﬂies
of a particular genotype (TI ¼
P
[tumor size 3 n]/N, where n is the
number of occurrences for a particular tumor size and N is the total
number of ﬂies counted for a particular genotype). Tumor size 1 is
deﬁned as a tumor with a diameter equal to the width of an average
abdominal segment (see Figure 1A). TI 1.0 is equivalent to all ﬂies of a
category each having a 1.0 size tumor.
To eliminate genetic background effects, hop
Tum-l and Kr
1 hetero-
zygotes were outcrossed to a y
1 w
1 stock for ten generations. hop
Tum-l
was monitored by the presence of melanotic tumors in the females in
each generation. To recover Kr
1 from the outcrossed progeny, ten yw
virgin females were selected after ﬁve generations of outcrossing and
individually crossed to a y
1 w
1; Sco/CyO ftz-lacZ stock (in y
1 w
1
background). Three males from the F1 of each cross were individually
backcrossed to y
1 w
1; Sco/CyO ftz-lacZ ﬂies (to maintain a stock) and the
same male was testcrossed to Kr
2/CyO ﬂies. The presence of Kr
1 was
inferred by noncomplementation in the testcross, and a y
1 w
1; Kr
1/CyO
ftz-lacZ male was used to repeat the same outcrossing procedure one
more round to establish an outcrossed y
1 w
1; Kr
1/CyO ftz-lacZ stock.
Antibodies, drug treatment, and embryonic phenotypes. Anti-
H3Ac and anti-H3 (both from Upstate, http://www.upstate.com/) were
used as 1:1,000 dilutions in Western blots, sheep anti-5-meCytidine
(Abcam, http://www.abcam.com/) was used for precipitating methy-
lated DNA. For treatment with HDAC or methyltransferase inhib-
itors, ﬂies were cultured in food containing TSA (4.5 lM; Sigma,
http://www.sigmaaldrich.com/), sodium butyrate (10 mM, Sigma), or 5-
aza-dC (100 lM; MP Biomedicals, http://www.mpbio.com) at 25 8C. To
detect b-gal expression from the ftz-lacZ transgene, mouse anti-b-gal
(1:1,000; Promega, http://www.promega.com/) and a biotinylated
secondary antibody and the ABC Elite Kit (Vector Laboratories,
http://www.vectorlabs.com/) were used for whole-mount immunos-
taining of embryos. Signals were detected with DAB solution
according to the manufacturer’s recommendations. Stained embryos
were dehydrated with ethanol, mounted with Euparal, and photo-
graphed with an Axiophot microscope using DIC optics.
Analyses of genomic DNA methylation. Gemonic DNA was isolated
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instructions with minor modiﬁcations. Thirty 1–2-d-old adult ﬂies or
100 ll of 0–12-h embryos of desired genotypes were homogenized in
180 ll of PBS and 20 ll of proteinase K (1 mg/ml) per manufacturer’s
protocol. The samples were treated with DNase-free RNase A (Sigma)
for 2 h at 37 8C prior to column puriﬁcation. For restriction digests, 3
lg of genomic DNA was incubated with 10 units of BstUI (New
England Biolabs, http://www.neb.com/) or 10 units of HaeIII (New
England Biolabs) in 60 ll of total volume at 37 8C. At different time
points, an aliquot of the digests was removed and heated at 80 8Ct o
inactivate the restriction enzyme. One microliter of each sample was
used for PCR ampliﬁcation with primers speciﬁc to ftz-lacZ (forward:
59-CCCAGGGATCGGACGTAATGTTAT-39; reverse: 59-GGATGTGC
TGCAAGGCGATTAAGT-39). Bisulﬁte treatment was carried out with
the EpiTect Bisulﬁte Kit (Qiagen, http://www1.qiagen.com/) according
to the manufacturer’s instructions. Genomic DNA (2 lg) was treated
in Bisulﬁte Mix. Treated genomic DNA was ampliﬁed with the
following strand-speciﬁc primers (forward: 59-TTTAGGGATTG
GATGTAATGTTAT-39; reverse: 59-AAATATACTACAAAACAATTA
AAT-39). The PCR fragments were cloned into pGEM-T vectors
(Promega) and independent plasmid DNA isolates were sequenced.
Sequencing was carried out by Gene Gateway (http://www.
genegateway.com/). For immunoprecipitation, genomic DNA was
ﬁrst digested to completion with EcoRI and BamHI (New England
Biolabs). Digested genomic DNA (2 lg) in 200 ll was used for
immunoprecipitation with 5 ll of anti-5-meC (Abcam) or control
antibody at 4 8C overnight, together with protein-G beads that had
been preabsorbed with sonicated single-stranded salmon sperm DNA.
The antibody complex was centrifuged and washed and eluted. The
presence of ftz-lacZ promoter sequence was quantiﬁed by PCR with
the above primers.
Supporting Information
Figure S1. Full-Length Western Gel Images for Figure 1E
Found at doi:10.1371/journal.pgen.0030151.sg001 (1.5 MB JPG).
Figure S2. The ftz Minimal Enhancer
Partial sequence of the ftz-lacZ transgene is shown. PCR primers used
in ampliﬁcation of the genomic fragment are indicated in green and
purple. Numbers correspond to nucleotide position of the PCR
fragment. Two CG or CT-rich sequences are boxed in red.
Found at doi:10.1371/journal.pgen.0030151.sg002 (1.6 MB JPG).
Table S1. Accession Numbers for Mutations Used in This Study
Found at doi:10.1371/journal.pgen.0030151.st001 (21 KB XLS).
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